2003New England Journal of MedicineRequires access

Contrast-Agent–Induced Acute Renal Dysfunction — Is Iodixanol the Answer?

Carl M. Sandler

Open publisher page 63 citations

Abstract

In this issue of the Journal, Aspelin et al.1 report findings from a prospective, randomized, double-blind trial that compared iodixanol, a third-generation, iso-osmolar, dimeric, nonionic iodinated contrast agent, with iohexol, a low-osmolar, monomeric, nonionic contrast agent. The use of iodixanol resulted in significantly fewer nephrotoxic effects in high-risk patients undergoing arteriography than iohexol did — findings that are important because a beneficial effect of this iso-osmolar agent on renal function had not previously been conclusively demonstrated in a randomized study.Before the late 1960s, all iodinated contrast agents used for radiologic imaging were ionic monomers with an ionizing carboxyl group . . .

About this research paper

What this paper is about

In this issue of the Journal, Aspelin et al.1 report findings from a prospective, randomized, double-blind trial that compared iodixanol, a third-generation, iso-osmolar, dimeric, nonionic iodinated contrast agent, with iohexol, a low-osmolar, monomeric, nonionic contrast agent. The use of iodixanol resulted in significantly fewer nephrotoxic effects in high-risk patients undergoing arteriography than iohexol did — findings that are important because a beneficial effect of this iso-osmolar agent on renal function had not previously been conclusively demonstrated in a randomized study.Before the late 1960s, all iodinated contrast agents used for radiologic imaging were ionic monomers with an ionizing carboxyl group . . .

Why it matters

OpenAlex reports 63 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In this issue of the Journal, Aspelin et al.1 report findings from a prospective, randomized, double-blind trial that compared iodixanol, a third-generation, iso-osmolar, dimeric, nonionic iodinated contrast agent, with iohexol, a low-osmolar, monomeric, nonionic contrast agent. The use of iodixanol resulted in significantly fewer nephrotoxic effects in high-risk patients undergoing arteriography than iohexol did — findings that are important because a beneficial effect of this iso-osmolar agent on renal function had not previously been conclusively demonstrated in a randomized study.Before the late 1960s, all iodinated contrast agents used for radiologic imaging were ionic monomers with an ionizing carboxyl group . . .

Key concepts: Iodixanol, Iohexol, Medicine, Iodinated contrast, Nephrotoxicity, Contrast (vision), Randomized controlled trial, Iopromide

Related papers

Back to paper searchBrowse research topicsOriginal source
Contrast-Agent–Induced Acute Renal Dysfunction — Is Iodixanol the Answer? — Research Paper | ScholarLens